文献速递糖尿病

雷帕霉素联合维格列汀恢复长期1型糖尿病β细胞功能:双盲随机试验

Rapamycin Plus Vildagliptin to Recover β-Cell Function in Long-Standing Type 1 Diabetes: A Double-Blind, Randomized Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

这项2期双盲随机安慰剂对照试验纳入55例长期1型糖尿病患者,随机分为雷帕霉素4周组、雷帕霉素4周联合维格列汀12周组或双安慰剂组。主要结局为第4周和第12周混合餐耐量试验C肽阳性反应比例,结果各组均无患者出现阳性反应。雷帕霉素组胰岛素需求量下降,12周时糖化血红蛋白显著降低,但β细胞功能未恢复。

要点

  • 雷帕霉素联合维格列汀未使长期1型糖尿病患者C肽反应阳性。
  • 雷帕霉素组第4周胰岛素需求量显著下降。
  • 第12周雷帕霉素组和联合组糖化血红蛋白均显著降低。

核心结论

  • 雷帕霉素降低胰岛素需求量,但未恢复长期1型糖尿病患者的β细胞功能。

研究设计与样本

  • 2期、单中心、随机、双盲、安慰剂对照研究,55例长期1型糖尿病患者按1:1:1随机分为三组。

主要发现

  • 主要结局:各组均无患者出现C肽阳性反应(90分钟C肽>0.2 nmol/L),第4周和第12周无显著差异。
  • 雷帕霉素治疗与胰岛素抗体滴度下降及激素/免疫谱改变相关。

临床怎么用

  • 雷帕霉素虽未恢复β细胞功能,但可考虑用于短期降低长期1型糖尿病患者的胰岛素需求量和改善血糖控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of this study was to investigate whether treatment with rapamycin plus vildagliptin restores β-cell function in patients with long-standing type 1 diabetes. METHODS: A phase 2, single-center, randomized, double-blind, placebo-controlled study was conducted in long-standing type 1 diabetes patients randomly assigned (1:1:1) to 4 weeks of rapamycin (group 2), 4 weeks of rapamycin plus 12 weeks of vildagliptin (group 3), or double placebo (group 1). The primary outcome was the proportion of participants with a positive response to the Mixed-Meal Tolerance Test (C-peptide at 90 minutes > 0.2 nmol/L) at weeks 4 and 12. Secondary end points included insulin requirement, standard measures of glycemic control, and hormonal and immunological profile. RESULTS: Fifty-five patients were randomly assigned to group 1 (n = 18), group 2 (n = 19), or group 3 (n = 18). No patient in any group showed a positive C-peptide response, and there was no significant difference at 4 and 12 weeks for the primary outcome. At 4 weeks, insulin requirement decreased from 0.54 to 0.48 U/kg/day in group 2 (P = .013), from 0.59 to 0.51 U/kg/day in group 3 (P < .001), whereas it did not change in group 1. At 12 weeks, glycated hemoglobin significantly decreased both in group 2 (from 7.3% [56 mmol/mol] to 7% [53 mmol/mol]; P = .045] and in group 3 (from 7.2% [55.5 mmol/mol] to 6.9% [52 mmol/mol]; P = .001]. Rapamycin treatment was associated with a decrease in insulin antibody titer and changes in hormonal/immunological profile. CONCLUSIONS: Rapamycin reduced insulin requirement, but did not restore β-cell function in patients with long-standing type 1 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bolla AM, Gandolfi A, Borgonovo E, et al. Rapamycin Plus Vildagliptin to Recover β-Cell Function in Long-Standing Type 1 Diabetes: A Double-Blind, Randomized Trial. J Clin Endocrinol Metab. 2021. PMID: 33124663. doi:10.1210/clinem/dgaa791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。